Nuclear Medicine and Biology
Volume 37, Issue 4 , Pages 509-516 , May 2010

Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation

Received 5 December 2008 ,Revised 6 December 2009 ,Accepted 30 December 2009.

References 

  1. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem. 1999;274:18438–18445
  2. Kehler J, Ritzen A, Greve DR. The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin Ther Pat. 2007;17:147–158
  3. Xie Z, Adamowicz WO, Eldred WD, Jakowski AB, Kleiman RJ, Morton DG, et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience. 2006;139:597–607
  4. Fujishige K, Kotera J, Omori K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem. 1999;266:1118–1127
  5. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem. 2006;54:1205–1213
  6. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 2003;985:113–126
  7. Soderling SH, Bayuga SJ, Beavo JA. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci U S A. 1999;96:7071–7076
  8. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006;51:386–396
  9. Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology. 2006;51:374–385
  10. Belpaire FM, Bogaert MG. The excretion of 3H-papaverine in the rat. Biochem Pharmacol. 1973;22:59–66
  11. Ithakissios SD, Tsatsas G, Nikokavouras J, Tsolis A. Synthesis of papaverine and quinopavine specifically labeled with 14C. J Label Compounds. 1974;10(3):369–379
  12. Brochmann-Hanssen E, Hirai K. Opium alkaloids. VII. Isolation of a new benzylisoquinoline alkaloid. Synthesis and NMR studies of papaveroline trimethyl ethers. J Pharm Sci. 1968;57:940–943
  13. Brossi A, Teitel S. Selective O-demethylation of papaverine. J Org Chem. 1970;35:1684–1687
  14. Walker KA, Boots MR, Stubbins JF, Rogers ME, Davis CW. 1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors. J Med Chem. 1983;26:174–181
  15. Rae ID, Simmonds PM. The structure of papaverine in solution as determined by proton nuclear magnetic relaxation methods. Aust J Chem. 1987;40(5):915–923
  16. Belpaire FM, Bogaert MG. Metabolism of papaverine. II. Species differences. Xenobiotica. 1975;5:421–429
  17. Belpaire FM, Rosseel MT, Bogaert MG. Metabolism of papaverine IV. Urinary elimination of papaverine metabolites in man. Xenobiotica. 1978;8:297–300

PII: S0969-8051(10)00002-8

doi: 10.1016/j.nucmedbio.2009.12.012

Nuclear Medicine and Biology
Volume 37, Issue 4 , Pages 509-516 , May 2010

Article Tools

* Image Usage & Resolution